SEMAGLUTIDE.blog
Open menu · English
Purple illustration of a 31-unit peptide chain with a fatty side chain, representing semaglutide
GLP-1 RECEPTOR AGONIST · ONCE WEEKLY

Semaglutide. The Peptide Behind a Medical Shift

Semaglutide changed how doctors treat type 2 diabetes and obesity. This site explains what the molecule is, what the big studies showed and where the limits of the evidence lie, in plain English with sources.

Semaglutide is sold as the prescription medicines Ozempic, Rybelsus and Wegovy. Powder sold as research-grade semaglutide is not one of those medicines, has no marketing authorisation and is meant for laboratory work. This site only informs.

Mimics the gut hormone GLP-1
Developed by Novo Nordisk in Denmark
Available as a weekly injection and a daily tablet

A Short Introduction

Semaglutide is a man-made version of GLP-1, a hormone the intestine releases after we eat. Natural GLP-1 disappears from the blood within about two minutes. Chemists at Novo Nordisk changed the molecule so that a single dose keeps working for a whole week.

The first semaglutide medicine, Ozempic, was approved for type 2 diabetes in 2017. A daily tablet followed in 2019, and a higher-dose injection for weight management, Wegovy, in 2021. In the STEP 1 study, adults with obesity lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo.

Later studies looked beyond blood sugar and weight, at heart attacks and strokes, kidney disease, heart failure and fatty liver disease. Each topic on this site links to the original papers, so you can check the numbers yourself.

Key Facts

Drug classGLP-1 receptor agonist (incretin mimetic)
Structure31 amino acids, 94% identical to human GLP-1, with an 18-carbon fatty acid chain
TargetThe GLP-1 receptor
CompanyNovo Nordisk A/S (Bagsværd, Denmark)
Duration of actionHalf-life of roughly one week in people
MedicinesOzempic (weekly injection), Rybelsus (daily tablet), Wegovy (weekly injection for weight management)
StatusAvailable only on prescription in Europe, the UK, the US and most other countries

Before You Read On

Nothing on Semaglutide.blog is medical advice, and it should not guide any decision about your own treatment. Research-grade semaglutide is a laboratory reagent. It is not intended for people and should never be used as a substitute for a prescribed medicine.

Browse the Topics

What is Semaglutide?How semaglutide copies GLP-1 and why one dose lasts a week HistoryFrom the discovery of GLP-1 to Ozempic, Rybelsus and Wegovy StudiesWhat the SUSTAIN, PIONEER, STEP, SELECT and FLOW studies found Legal & SafetyApproved uses, side effects and the warnings regulators added For ResearchersBasic points for laboratories that need research material